论文部分内容阅读
目的观察吉非替尼治疗晚期非小细胞肺癌的疗效及毒副反应。方法30例经放、化疗治疗失败的非小细胞肺癌患者,其中5例肿瘤局限于胸腔内,25例已有远处转移。吉非替尼剂量为250 mg/d,口服,每天1次,全组用药的中位时间为4个月。结果30例患者中,完全缓解1例,部分缓解8例,稳定10例,进展11例。全组有效率30.0%,疾病控制率为63.3%,中位生存期5.3个月(1~18个月),1年生存率为43.3%。主要毒副作用是皮疹,共发生11例,占36.7%;其他毒副作用为腹泻,转氨酶升高。结论吉非替尼对放、化疗失败的晚期非小细胞肺癌有较好的治疗效果,且毒副反应轻。
Objective To observe the efficacy and side effects of gefitinib in the treatment of advanced non-small cell lung cancer. Methods Thirty patients with non-small cell lung cancer who had failed radiotherapy or chemotherapy were enrolled. Among them, 5 cases were localized in the thoracic cavity and 25 cases had distant metastasis. Gefitinib dose of 250 mg / d, orally, once daily, the median time for the whole group of medication for 4 months. Results Among 30 patients, complete remission in 1 case, partial remission in 8 cases, stable in 10 cases and progression in 11 cases. The total effective rate was 30.0%, the disease control rate was 63.3%, the median survival time was 5.3 months (1 ~ 18 months), and the 1-year survival rate was 43.3%. The main side effects were rashes, a total of 11 cases, accounting for 36.7%; other side effects of diarrhea, elevated transaminases. Conclusion Gefitinib has good therapeutic effect on advanced non-small cell lung cancer with failed radiotherapy and chemotherapy, and has mild toxicity.